Vera Therapeutics beats second quarter 2026 EPS estimates as TRUTAKNA commercial launch begins

Vera Therapeutics reported a second quarter 2026 net loss of $109.5 million, or $1.52 per share, which narrowed from the $1.60 loss expected by analysts. While the company generated no revenue during the period, it achieved a milestone with the July 2026 FDA accelerated approval of TRUTAKNA for primary IgA nephropathy, marking its transition to a commercial-stage biotechnology firm.

Key Highlights

• Management reported a strong liquidity position with $499.2 million in cash and marketable securities as of June 30.
• Operating expenses rose to $112.5 million, driven largely by a 138% year-over-year increase in G&A to $52.4 million to support commercial infrastructure.
• The company reached alignment with the FDA for an earlier ORIGIN 3 efficacy analysis, with results now expected in the third quarter of 2026.